GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Capital Expenditure

Opthea (FRA:UKJ) Capital Expenditure : €-0.03 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Opthea Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Opthea's cash flow for capital expenditures for the six months ended in Jun. 2024 was €-0.03 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03 Mil.

Opthea Capital Expenditure Historical Data

The historical data trend for Opthea's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Capital Expenditure Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 -0.02 -0.02 -0.03

Opthea Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 - -0.03

Opthea Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Capital Expenditure
Comparable Companies
ASX:CUV ASX:PYCDA ASX:BOT ASX:IMM ASX:IMU ASX:RAC ASX:ALA ASX:DXB ASX:LTP ASX:OCC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CKDXF:USA OPT:USA OPT:Australia
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Website
https://www.opthea.com
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines